Skip to main content

BG Medicine Regains Nasdaq Compliance

NEW YORK (GenomeWeb News) – BG Medicine said in a filing with the US Securities and Exchange Commission today that it has regained compliance with Nasdaq listing requirements.

BG disclosed a couple of weeks ago that the Listing Qualifications Department of the Nasdaq Stock Market had informed the firm that the market value of its listed securities had closed below the minimum $50 million required for continued listing for the 30 days leading up to Dec. 10. The company was given until June 10, 2013, to regain compliance with the rule.

Nasdaq told the firm on Dec. 27 that it had regained compliance because for the consecutive business days ending Dec. 24 the market value of its listed securities was $50 million or greater.

Waltham, Mass.-based BG Medicine makes the CardioScore and Galectin-3 heart failure tests.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.